Assess whether to resubmit, meet, or pause the program (6e2b20)

SITUATION A mid-size sponsor after a complete response letter cannot treat a CRL citing manufacturing, not efficacy as incidental context on scientific-advice briefing book. 505(b)(2) development lead must close to resubmit, meet, or from that extract under Pharma & Life Sciences / Clinical and Evidence Strategy.

DECISION 505(b)(2) development lead in a mid-size sponsor after a complete response letter must choose To resubmit, meet, / Pause the program using scientific-advice briefing book after a CRL citing manufacturing, not efficacy.

HYPOTHESES TO TEST 1. A CRL citing manufacturing, not efficacy is noise around an already-controlled Clinical and Evidence Strategy process in a mid-size sponsor after a complete response letter, given scientific-advice briefing book. 2. A CRL citing manufacturing, not efficacy is the event in scientific-advice briefing book that forces To resubmit, meet, for 505(b)(2) development lead under Pharma & Life Sciences. 3. Scientific-advice briefing book shows a one-file miss after a CRL citing manufacturing, not efficacy, not a Clinical and Evidence Strategy program failure. 4. Scientific-advice briefing book cannot decide to resubmit, meet, or yet after a CRL citing manufacturing, not efficacy; hold is the only Pharma & Life Sciences close a mid-size sponsor after a complete response letter can defend.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 2. Check whether scientific-advice briefing book supports the labeled claim 505(b)(2) development lead would keep. 3. Map FDA-response timing and owner in a mid-size sponsor after a complete response letter. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read scientific-advice briefing book against a CRL citing manufacturing, not efficacy and write the one fact that would move to resubmit, meet, or for 505(b)(2) development lead.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (scientific-advice briefing book after a CRL citing manufacturing, not efficacy). Lead with the Pharma & Life Sciences option scientific-advice briefing book can support after a CRL citing manufacturing, not efficacy, then the two facts that force it, then the Monday action for 505(b)(2) development lead in a mid-size sponsor after a complete response letter.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in scientific-advice briefing book, then the action for 505(b)(2) development lead - Hypothesis scorecard against scientific-advice briefing book: supported / rejected / untestable - Missing page in scientific-advice briefing book after a CRL citing manufacturing, not efficacy, if any - Regulatory or exam hook Clinical and Evidence Strategy would cite